Purine derivative compounds for medical use

US10561661B2 · kind B2 · utility

Assignees

• MANROS THERAPEUTICS · FR
• THE UNIVERSITY OF CHICAGO · US

Inventors

• Laurent Meijer · Morlaix, FR
• Nassima Oumata · Paris, FR
• Herve Galons · Paris, FR
• Aida Gabdoulkhakova · Chicago, US
• Vladimir Riazanski · Clarendon Hills, US
• Deborah Nelson · Knoxville, US

Key dates

• Filing date: Feb 17, 2015
• Grant date: Feb 18, 2020
• Expiry date: Mar 2, 2035

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N33/5091
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method for treatment of disease by reduction in macrophages-mediated bacterial killing, including administration to patients in need a compound of formula (I): wherein A is N or CH; B is NO, or S; R1 is H, (C1-C4)alkyl group, methyl(C1-C6)cycloalkyl group or (C1-C6)cycloalkyl group; R2 is an aryl, arylmethyl group or methylheteroaryl group as methylpyridine and methylthiophene; R3 is absent when B is O or S, or is H or (C1-C4)alkyl group when B is N; R4 is (C1-C5)alkyl group or (C1-C4)cycloalkyl group, groups bearing a carboxylic acid group, and (C1-C5)alkyl group or (C1-C4)cycloalkyl substituted by hydroxyl group, halogen group or methoxy group, when B is N, R3 and R4 can together form a 5- or 6-membered heterocycle substituted by carboxylic acid group, substituted by a halogen atom, hydroxyl group, methoxy group or hydroxymethyl group, or pharmaceutically acceptable salt. Also provided are new compounds relating to this use.